BUSINESS● LOWSep 23 · Sep 23, 2026, 3:03 PM
Compass Therapeutics downgraded at Wedbush as FDA seeks additional trial for lead asset
Seeking Alpha Tech · north america
Compass Therapeutics received a downgrade from Wedbush after the FDA requested an additional trial for its lead asset. This regulatory decision has implications for the company's product development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS16m agoBGFI: Henri-Claude Oyima succeeds in his bet on the stock market introduction in two phasesJeune AfriqueBUSINESS16m agoMan City charges: Maresca says club, players, fans are ‘more together’Vanguard Nigeria